Chronic prostatitis — most commonly chronic pelvic pain syndrome (CPPS) — affects a significant number of men worldwide, and many have already tried antibiotics, alpha-blockers or anti-inflammatories without lasting relief. Extracorporeal Shock Wave Therapy (ESWT) is a non-invasive treatment that uses focused acoustic pulses to reduce pelvic pain and improve urinary and sexual symptoms in men with CPPS. It's supported by multiple placebo-controlled trials, a formal recommendation from the American Urological Association, and, as of 2023 and 2024, two independent meta-analyses covering hundreds of patients — making it one of the better-evidenced non-drug options available for men who haven't responded to standard treatment.
At a glance
- ESWT is non-invasive, drug-free, and typically delivered over 4–8 weekly sessions.
- A 2023 analysis pooling over 650 men across more than a dozen clinical trials found consistent improvements in pain, urinary symptoms and quality of life.
- A separate 2024 review reached the same conclusion independently, strengthening confidence in the result.
- The American Urological Association formally recommends that clinicians discuss ESWT with CP/CPPS patients — one of the higher grades of evidence a guideline can give.
- In one trial, roughly 4 in 5 men improved with real treatment, compared with about 1 in 4 given a placebo.
- Benefit typically peaks around 6 months, with a gradual, partial decline for some men by 9–12 months — though most remain better than their starting point.
- Reported side effects are minimal — mild, temporary discomfort at the treatment site is the most common.
- ESWT works best as part of a multimodal plan, not as a stand-alone cure — often combined with pelvic floor physiotherapy, tadalafil, or lifestyle changes.
What is shockwave therapy (ESWT) for prostatitis?
Extracorporeal shock wave therapy uses focused, low-intensity acoustic pulses delivered through the skin to the perineum (the area between the scrotum and anus) and surrounding pelvic tissue. It was originally developed for breaking up kidney stones (lithotripsy) — a much higher-intensity application — and later adapted, at low intensity, for musculoskeletal and chronic pain conditions, including CPPS, where it's used to calm inflammation and nerve sensitivity rather than break anything up.
Two main types of device are used in current practice: focused shockwave devices, which concentrate energy at a specific depth, and radial devices, which disperse energy more broadly near the skin surface. A 2026 review comparing the two found both are used effectively for CP/CPPS, though device choice and protocol still vary between centres — this is a rapidly-evolving, actively-researched area rather than a single fixed technique.
How does ESWT actually help CPPS?
The exact mechanism isn't fully settled, but research points to several overlapping effects rather than one single action:
- Reduces local inflammation. Laboratory studies show ESWT lowers inflammatory markers in prostate tissue, partly by dampening a signalling pathway involved in ongoing inflammation.
- Calms nerve sensitisation. CPPS often involves nerves in the pelvic region becoming persistently over-sensitive, amplifying pain signals beyond what's happening in the tissue itself. Animal studies using brain imaging suggest ESWT can reduce this central sensitisation, not just act on the prostate locally.
- Improves local blood flow. As with ESWT's use in other conditions, increased blood flow to treated tissue is thought to support healing and reduce pain signalling.
It's worth noting that the exact mechanism, and exactly which patients respond best, are still active areas of research rather than fully settled science. Some specialists have pointed out that improved blood flow or reduced inflammation alone may not fully explain why some men benefit and others don't — patient selection for ESWT is still being refined, and treatment is best seen as one option to discuss with your specialist rather than a guaranteed fix for every man with CPPS.
This combination of possible effects — anti-inflammatory, nerve-calming and circulatory — is likely why ESWT can help even when standard antibiotics (aimed only at infection) have failed. It's also why response isn't universal: men whose symptoms are driven mainly by pelvic floor muscle tension or inflammation tend to respond better than those whose symptoms have other dominant causes — which is why ESWT is usually considered alongside, not instead of, a broader symptom assessment (see the UPOINT framework on our CPPS page).
What does the evidence actually show?
- The American Urological Association (AUA) 2025 guideline gives ESWT a formal recommendation for CP/CPPS: clinicians should discuss low-intensity extracorporeal shockwave therapy with patients — one of the higher grades of evidence a guideline can give a treatment.
- The European Association of Urology (EAU) guidelines cite a trial in which just over half of men improved on the pain scale with ESWT, compared with roughly 1 in 5 given a placebo, after 12 weeks of treatment.
- A 2023 analysis pooling data from more than a dozen randomised controlled trials, totalling over 650 men, found consistent improvements in pain, urinary symptoms, erectile function and quality-of-life scores with low-intensity ESWT, whether used alone or alongside medication.
- A 2024 review (an entirely separate research team) independently reviewed the available placebo-controlled evidence and reached a similarly positive conclusion on pain relief and quality of life — two separate teams arriving at the same result strengthens confidence beyond any single study.
- The original placebo-controlled trial that established ESWT as a credible CPPS treatment found significant improvement in pain and quality of life compared with sham treatment.
- A more recent double-blind, placebo-controlled trial confirmed the benefit specifically in non-inflammatory CPPS (type IIIb).
- In a trial of a newer ESWT device, about 4 in 5 men responded to real treatment, compared with roughly 1 in 4 who received a placebo — one of the clearer head-to-head comparisons in the current literature.
It's worth being upfront that long-term benefit is less settled than short-term benefit. The EAU guidelines note that while short-term trials show clear improvement, a subsequent meta-analysis found long-term efficacy was not statistically significant, and one follow-up study found no measurable effect remaining at 24 weeks. This doesn't mean ESWT doesn't work — most men do respond in the short-to-medium term — but it does mean some men may need a repeat course rather than expecting one-off, permanent results.
As with most CPPS research, individual study sizes are still relatively modest (typically 20–150 patients) and protocols vary between centres — but the direction of evidence across multiple independent, placebo-controlled trials, now backed by two separate meta-analyses and a formal guideline recommendation, is consistent.
Who is a good candidate for ESWT?
ESWT tends to be considered for men who:
- Have chronic pelvic pain syndrome (CPPS) — sometimes called type III or non-bacterial prostatitis — rather than an active bacterial infection
- Have had symptoms for at least 3 months
- Have not had adequate relief from first-line treatments such as alpha-blockers, tadalafil or anti-inflammatories
- Do not have an active pelvic infection or a bleeding disorder that would make treatment unsuitable
The strongest trial evidence specifically covers non-inflammatory CPPS (type IIIB), though research in inflammatory CPPS (type IIIA) is more limited. If your test results have come back normal despite ongoing symptoms, our article on why prostatitis tests can be normal explains why — and how this fits into diagnosis. Your urologist will assess which category best fits your symptoms before recommending ESWT.
What does treatment actually involve?
- Sessions typically last around 15–20 minutes.
- A standard protocol delivers around 3,000 pulses to several sites around the perineum and prostate area, usually once a week for 4–6 weeks (more intensive twice-weekly protocols, or courses extending to 8 sessions, are sometimes used).
- No anaesthetic is required, and most men return to normal activity immediately afterwards.
- You lie in a comfortable position (often similar to a prostate examination position) while the handheld device is applied to the perineal skin.
- Symptom improvement is usually first noticed from around 4 weeks into the course, not immediately after the first session, with benefit typically continuing to build for several months afterwards.
How does ESWT compare with other CPPS treatments?
CPPS rarely responds fully to any single treatment, which is why most specialists combine several approaches rather than relying on one. Compared with these:
- Versus antibiotics: Antibiotics target bacterial infection, which is absent in the large majority of CPPS cases. ESWT instead targets inflammation and nerve sensitisation directly, which is why it can help even when antibiotics have already failed.
- Versus tadalafil: Tadalafil is a daily tablet that improves pelvic blood flow and smooth muscle relaxation (see our tadalafil for CPPS article — the same medication class discussed on our impotence and erectile dysfunction page). ESWT is a course-based physical treatment rather than an ongoing medication — the two are often used together rather than as alternatives.
- Versus pelvic floor physiotherapy: Physiotherapy and pelvic floor exercises directly address muscle tension and are often recommended alongside ESWT, particularly for men whose symptoms are strongly linked to pelvic floor dysfunction.
Is ESWT safe? What are the side effects?
ESWT has a strong safety record across the trials reviewed above, with no serious treatment-related complications reported in the studies cited on this page. Some men notice mild, temporary discomfort, redness or bruising at the treatment site, which typically settles quickly. It's not suitable for everyone — for example, men with certain bleeding disorders or active pelvic infection should discuss this with their urologist first.
Myth vs. fact
Myth: "Shockwave therapy is only for kidney stones."
Fact: That's a different, much higher-intensity form of shockwave (lithotripsy). ESWT for CPPS uses low-intensity pulses aimed at reducing inflammation and pain, not breaking anything up.
Myth: "If antibiotics didn't work, nothing will."
Fact: Most CPPS isn't caused by an active bacterial infection, so antibiotics were never likely to resolve it. ESWT targets inflammation and nerve sensitisation directly, which is why it can help even after antibiotics have failed.
Myth: "It's a quick fix — one session and you're done."
Fact: Benefit typically builds over a full course of 4–8 sessions, with improvement often first noticed around week 4 and continuing to build for months afterwards.
Myth: "The results are permanent."
Fact: Follow-up data suggests benefit can last many months but may gradually fade for some men after around 9–12 months, similar to other CPPS treatments. Some men benefit from a planned repeat course.
Frequently Asked Questions About Shockwave Therapy (ESWT) for Prostatitis
Does ESWT hurt?
Most men describe it as mild pressure or tapping rather than pain. Any discomfort is usually brief and settles shortly after the session ends.
How many sessions will I need?
Most protocols involve 4–6 weekly sessions, though some courses extend to 8, and your specialist may recommend a different schedule depending on your symptoms and response.
How soon will I notice an improvement?
Most men who respond begin noticing benefit from around 4 weeks into treatment, with improvement often continuing to build over the following months, peaking for many men around 6 months.
Do the results wear off over time?
Follow-up data suggests benefit is generally well maintained through the first 6 months, with some gradual fading possible after 9–12 months for some men. This varies between patients, and a repeat course can be considered if symptoms return.
Can ESWT be combined with other treatments?
Yes. ESWT is often used alongside pelvic floor physiotherapy, tadalafil, or other CPPS treatments as part of a broader, individualised plan rather than as a stand-alone therapy.
Is ESWT covered by insurance or the NHS?
Availability varies. Speak with your urologist or insurer directly to confirm coverage for your specific situation.
Does ESWT work for everyone?
No single CPPS treatment works for every patient, which is why treatment is usually tailored using a framework like UPOINT to identify which factors are driving your individual symptoms — see our full guide to CPPS for how this works. ESWT tends to help men whose symptoms are significantly linked to pelvic floor tension and localised inflammation, and the strongest evidence is in non-inflammatory (type IIIB) CPPS specifically.
What's the difference between focused and radial shockwave devices?
Focused devices concentrate energy at a specific depth in the tissue; radial devices spread energy more broadly near the surface. Both have supporting evidence for CP/CPPS, and device choice is typically based on your specialist's clinical judgement and equipment available.
Are the effects of ESWT backed by real evidence, or is this experimental?
ESWT for CPPS is supported by multiple randomised, placebo-controlled trials, a formal recommendation from the American Urological Association, and two independent systematic reviews. It's an active, well-researched area rather than an unproven or experimental treatment, though it's still considered a second-line option after standard first treatments have been tried.
Will I need a repeat course?
Some men benefit from a single course lasting many months to over a year; others notice symptoms gradually return and opt for a repeat course. The topic will be discussed as part of your ongoing care.
Is ESWT painful during the actual pulses?
Most men tolerate it well without anaesthetic. Sensations are usually described as tapping or mild pressure rather than sharp pain, though sensitivity varies between individuals.
Can I drive or work immediately after a session?
Yes. There's no sedation involved, and most men resume normal activities, including driving and work, straight after each session.
Ready to book a consultation?
Mr Edward Calleja is an NHS and private Urology Consultant based in the South East of England, seeing patients across Sussex, Brighton, Eastbourne and Hastings, offering ESWT as part of an individualised treatment plan for men with chronic prostatitis/CPPS.
Related Posts
- Why Are My Prostatitis Tests Normal? Understanding CPPS and PPS
- Chronic Pelvic Pain Syndrome (CPPS): prostatitis
- Does Tadalafil (Cialis) Help Chronic Prostatitis (CPPS)?
- Kegel Exercises for Men: Pelvic Floor Benefits
- Main Prostatitis page
References
- American Urological Association. Diagnosis and Management of Male Chronic Pelvic Pain (CP/CPPS and CSCP): AUA Guideline. 2025. auanet.org/guidelines-and-quality/guidelines/male-chronic-pelvic-pain
- European Association of Urology. EAU Guidelines on Chronic Pelvic Pain — Management chapter. 2025 edition. uroweb.org/guidelines/chronic-pelvic-pain/chapter/management
- Kong X, Hu W, Dong Z, et al. The efficacy and safety of low-intensity extracorporeal shock wave treatment combined with or without medications in Chronic prostatitis/chronic pelvic pain syndrome: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023;26:483–494.
- Labetov D, et al. Extracorporeal shockwave therapy in treatment of chronic prostatitis/chronic pelvic pain syndrome: systematic review and meta-analyses. Neurourol Urodyn. 2024;43:1924–1937.
- Zimmermann R, Cumpanas A, Miclea F, Janetschek G. Extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome in males: a randomised, double-blind, placebo-controlled study. Eur Urol. 2009;56:418–424.
- Kim KS, Choi YS, Bae WJ, et al. Efficacy of low-intensity extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome IIIb: a prospective-randomized, double-blind, placebo-controlled study. World J Mens Health. 2022;40:473.
- Efficacy of the new P100 extracorporeal shock wave therapy device in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome: a sham treatment controlled, prospective clinical trial. Prostate Cancer Prostatic Dis. 2026.
- Skaudickas D, Lenčiauskas P, Skaudickas A, Undžytė G. Low intensity extracorporeal shockwave therapy for chronic pelvic pain syndrome: Long-term follow-up. 2023.
- Wu MJ, Kao CC, Yang MH, Tsao CW, Chen CL. Optimizing the Use of Extracorporeal Shock Wave Therapy for CP/CPPS: A Modality-Based Systematic Review and Meta-Analysis Comparing Focused and Radial Devices. J Clin Med. 2026;15:1270.
- Wang HJ, Tyagi P, Chen YM, Chancellor MB, Chuang YC. Low Energy Shock Wave Therapy Inhibits Inflammatory Molecules and Suppresses Prostatic Pain and Hypersensitivity in a Capsaicin Induced Prostatitis Model in Rats. Int J Mol Sci. 2019;20(19):4777.
